MINOCA
Myocardial injury with non-obstructive coronary arteries (5th UDMI 2026): suspected MI, no stenosis ≥50% — a working diagnosis; CMR confirms MI in only ~¼, the rest are mostly myocarditis, Takotsubo or cardiomyopathy. Workup: re-review angiogram (SCAD, branch occlusion), echo, CMR within 2 weeks ± OCT, then provocation testing for spasm/CMD. Treat the mechanism; everyone gets cardiac rehab.
MINOCA
Myocardial injury with non-obstructive coronary arteries (5th UDMI) — working diagnosis when suspected MI meets an angiogram with no stenosis ≥50%. After CMR, MI is the final diagnosis in only 22–27%; most have myocarditis, Takotsubo, cardiomyopathy or a non-cardiac cause (PE). Confirmed MI → reclassify as primary, secondary or procedure-related → myocardial injury and MI classification.
- 6–15% of MI; younger, ~2× more often female (1 in 8 MIs in women <55), more often NSTEMI than STEMI.
- Same angiogram, normal troponin → ANOCA/INOCA.
- Mimics: takotsubo syndrome, myocarditis → myopericarditis.
- SCAD with >50% obstruction is not MINOCA, but missed SCAD is often labelled MINOCA until OCT/IVUS or re-review → spontaneous coronary artery dissection.
- Prognosis not benign: death/MI ~2× that of matched patients without ASCVD; mimics have outcomes like obstructive MI → establish the cause during the admission.
coronary causes
| cause | mechanism | clue |
|---|---|---|
| plaque disruption (rupture, erosion, calcified nodule) — most common | thrombus on non-obstructive plaque ± distal embolisation | mild plaque in RWMA territory |
| vasospasm (epicardial or microvascular) → [[angina with non-obstructive coronary arteries | ANOCA]] | smooth-muscle hyperreactivity; triggers: smoking, cocaine, 5-FU, allergen (Kounis), phaeochromocytoma |
| coronary microvascular dysfunction (CMD) | impaired NO-mediated vasodilation → ↓ flow reserve | stress perfusion defect on CMR/PET |
| coronary embolism (<3%) | AF/LA thrombus, prosthetic valve, [[infective endocarditis | endocarditis]], paradoxical (PFO/ASD), thrombophilia |
| SCAD | intramural haematoma compresses lumen | young woman, FMD, peripartum, stressor |
HARP (2021) (women, OCT + CMR): OCT culprit in 46% (plaque disruption 43%); CMR non-ischaemic cause in 20%; combined abnormality in 85%. Cause unknown in 8–25% despite full workup.
diagnostic cascade
flowchart TD A["suspected MI, no stenosis ≥50%"] --> B["alternative explanation?<br/>Takotsubo, contusion, tachyarrhythmia,<br/>PE, cardiotoxin, severe sepsis"] B -- yes --> X["treat cause"] B -- no --> C["TTE (all)<br/>+ re-review angiogram:<br/>missed SCAD, branch occlusion, obstructive CAD"] C --> D["CMR in hospital (≤2 weeks)<br/>and/or return to cath lab for OCT"] D --> E["ischaemic LGE + oedema, one territory → MI → OCT for culprit"] D --> F["multifocal ischaemic LGE ± LV thrombus → embolism"] D --> G["stress perfusion defect → CMD"] D --> H["oedema, no LGE, non-coronary distribution → Takotsubo"] D --> I["subepicardial/mid-wall LGE + oedema → myocarditis"] E --> J["OCT negative → ACh provocation ± coronary physiology"]
CMR-first or OCT-first both acceptable by local access; transfer if neither available.
| test | tier | what it adds |
|---|---|---|
| hs-troponin (sex-specific), CBC, CRP | first-line | confirms injury; anaemia, inflammation, infection; supply–demand triggers |
| TTE (± contrast) | first-line, all | RWMA territory, Takotsubo pattern, cardiomyopathy, valve/pericardium, embolic source |
| CMR | first-line | within 2 weeks (Takotsubo oedema, mild myocarditis and small infarcts fade); still diagnostic in ≥50% later |
| OCT / IVUS | first-line | rupture/erosion/nodule, mural thrombus, SCAD, intimal bumping (spasm); OCT > IVUS for erosion |
| ACh / ergonovine provocation | supplementary | epicardial spasm (COVADIS: pain + ischaemic ECG + >90% constriction) or microvascular spasm; safe within 48 h; criteria → [[angina with non-obstructive coronary arteries |
| coronary physiology | supplementary | CFR, microcirculatory resistance → CMD; thresholds → [[angina with non-obstructive coronary arteries |
| CTA | supplementary | plaque, myocardial bridge; alternative if invasive angiography declined |
| PET flow | supplementary | ↓ myocardial flow reserve; limited Canadian access |
| TOE/bubble, thrombophilia | supplementary | suspected embolism → haematology |
CMR patterns
| LGE / oedema | diagnosis |
|---|---|
| subendocardial or transmural LGE + oedema, one coronary territory | infarct |
| ischaemic LGE in several territories ± LV thrombus | embolism |
| oedema without LGE, coronary distribution | vasospasm (severe spasm can give subendocardial LGE) |
| oedema without LGE, apical/mid/basal non-coronary distribution | takotsubo syndrome |
| subepicardial/patchy mid-wall LGE + oedema ± effusion | myocarditis → [[acute pericarditis |
| normal | best prognosis (10-y MACE ~3.5% vs ~47% with infarct) |
treatment by mechanism
Expert opinion — no RCT of pharmacotherapy specifically in MINOCA.
| cause | therapy | strength (CCS 2024) |
|---|---|---|
| plaque disruption | as obstructive MI: ASA + P2Y12 inhibitor (clopidogrel or ticagrelor), high-intensity statin (LDL ↓ >50% and <1.8 mmol/L), ACEi (class I) or ARB (IIa) if LVEF <40%, hypertension, diabetes or stable CKD, beta-blocker → post-MI care | per MI guidelines |
| SCAD | ASA + beta-blocker; conservative over PCI unless unstable; no routine statin → spontaneous coronary artery dissection | should be strongly considered |
| vasospasm | CCB ± nitrate; remove triggers; beta-blocker with caution → [[angina with non-obstructive coronary arteries | ANOCA]] |
| CMD | antianginals (beta-blocker, CCB, nitrate, ranolazine); ACEi + statin if otherwise indicated — ANOCA data favour beta-blocker + ACEi + statin first, CCB less certain → [[angina with non-obstructive coronary arteries | ANOCA]] |
| embolism | anticoagulate if AF, intracardiac or prosthetic valve thrombus; PFO/ASD closure if paradoxical; thrombophilia → haematology | per source guidelines |
| unknown cause | statin (all), ACEi/ARB; beta-blocker only if another indication; DAPT by most likely mechanism | may be considered |
| all | cardiac rehab (RCT n=524: ↓ death, MACE); risk factors; psychosocial support; allergen avoidance if Kounis; complex → women’s heart centre (BC, ON, QC, NS) | — |
- Statins: observational MACE HR 0.34–0.77; reaching LDL targets ↓ MACE 32% (SWEDEHEART). ACEi/ARB: meta-analysis (n=10 546) MACE HR 0.65, no mortality signal. DAPT and beta-blockers: null.
- SCAD without stent → DAPT benefit uncertain; menorrhagia → ASA alone.
Prepared 2026-10-19. Not yet verified — check every number against the sources.